STRATEC Biomedical earnings date
Want to see DE:SBS full AI Analyst Report?
STRATEC Biomedical (SBS) Q3 2026 Earnings Report
DE:SBS Q3 2026 EPS Results
- Actual EPS
- EUR 0.15
- Consensus EPS
- EUR 0.15
- Beat/Miss
- Met expectations
- One Year Ago EPS
- EUR 0.13
DE:SBS Q3 2026 Revenue Results
- Actual Revenue
- EUR 52.37M
- Expected Revenue
- EUR 58.50M
- Beat/Miss
- Missed by -EUR 6.13M
- YoY Revenue Growth
- -8.12%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- Before Open
- Conference Call
- Thursday, November 12, 2026
STRATEC Biomedical's next earnings date is estimated for March 31, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive. Management highlighted double-digit growth in core systems, strong third-quarter profitability, materially improved cash generation, lower net debt, a structurally improved margin profile following the Diatron divestiture, and constructive continuing-operations guidance. These positives were partly offset by lower reported revenue, the severe decline in Diatron hematology, ongoing service-parts weakness, negative reported earnings due to the Diatron valuation effect, limited visibility, and input-cost and regulatory pressures.
For 2026 continuing operations only, sales are expected to be stable to a slightly higher result at constant currency compared to pro forma 2025 sales of €223.5 million excluding Diatron, the adjusted EBIT margin is expected to be about 13% to 15%, and investments in tangible and intangible assets are expected to be 5% to 7% of sales; based on the current order forecast, the company expects a strong year-end, with around €76 million needed in the fourth quarter to reach the midpoint of sales guidance, while Diatron is expected to contribute around €20 million in sales and an adjusted EBIT margin of around minus €10 million for 2026, compared with approximately €30 million under the initial guidance given early this year.
- Double-Digit Growth in Core SystemsMolecular and immunoassay blood bank systems and complex sample preparation grew by double digits in the first 9 months. The company said its core platforms and instruments were performing very well.
- Strong Third-Quarter Profitability ImprovementThird-quarter adjusted EBIT grew by 36% in the opening summary and was later quantified as a 37% year-on-year increase. The adjusted EBIT margin reached 11.3%, an improvement of 370 basis points year on year.
- Improved Nine-Month Adjusted ProfitabilityNine-month adjusted EBIT increased 6.5% year on year, from €12.8 million to €13.7 million, while the adjusted EBIT margin improved by 100 basis points from 7.3% to 8.3%.
- Positive Adjusted Earnings and EPS GrowthAdjusted net income increased to €7.5 million from €7.1 million. Adjusted earnings per share rose from €0.58 to €0.62.
- Significant Cash Flow ImprovementNine-month operating cash flow increased to €39.4 million, compared with a negative €1.4 million in 2025. Free cash flow increased to €30.6 million from negative €14.8 million.
- Working-Capital-Driven Cash GenerationThe improvement in operating cash flow was mainly driven by working capital, particularly trade receivables, which declined from €56.9 million at year-end 2025 to €38.1 million at the end of September. Trade receivables contributed roughly €19 million of cash in the first 9 months, compared with a €5.9 million cash use in the prior period. Contract assets generated roughly €3 million of cash inflow, compared with an outflow of roughly €8 million in 2025.
- Reduced Net Debt and LeverageDespite cash declining to €21.2 million from €23.1 million at year-end 2025, net debt decreased significantly to €89 million from €112 million. Restated leverage following the Diatron divestiture was 2.3x net debt to EBITDA.
- Diatron Divestiture Supports Strategic FocusStratec signed an agreement on October 30 to sell 100% of Diatron, including its Hungarian, United States, and Indian businesses, to a consortium of investors from India. The transaction includes a fixed purchase price of €10 million plus potential earn-out payments. Stratec said the divestiture gives it a structurally better margin profile by focusing on fully integrated automated systems for high-end central labs and point-of-need markets, while molecular and immunoassay operations remain with Stratec.
- Improved Continuing-Operations Margin ProfileFor continuing operations excluding Diatron, nine-month sales were €101.8 million, adjusted EBIT rose from €17.2 million to €20.3 million, and the adjusted EBIT margin improved from 10.9% to 13.4%, despite slightly lower sales.
- Positive 2026 Continuing-Operations GuidanceFor continuing operations, the company expects sales to be stable to slightly higher at constant currency compared with pro forma 2025 sales of €223.5 million excluding Diatron. Adjusted EBIT margin guidance is approximately 13% to 15%, and investments in tangible and intangible assets are expected to be at the lower end of 5% to 7% of sales.
- Strong Year-End Order CoverageThe company expects a strong year-end. To reach the midpoint of sales guidance, it needs approximately €76 million in fourth-quarter sales, with the large majority of the required volume consisting of already contracted systems, service parts and consumables, and development and service work.
- Pipeline and Customer Interest Remain StrongStratec reported a noticeable increase in customers evaluating its platforms, very high demand for product life-cycle management projects, and good progress moving new developments into early-stage series production. The company will continue executing its deal pipeline and filling its early-stage development pipeline.
- Operational Readiness for Higher Manufacturing VolumesThe company said it is set up to deliver the elevated manufacturing volumes planned for the remainder of the year and will focus on complete and timely transfer of newly developed systems into series production at the expected quality.
- Efficiency Measures Supported MarginsEfficiency measures, particularly on personnel costs, contributed roughly €3 million, while product mix supported the company in overcoming the revenue decline. Management also said currency effects supported earnings generation, although it would not attribute the margin development to foreign exchange alone.
- Ongoing Collaboration Following Diatron SaleThe company said the Diatron transaction is not a clean break, as certain collaborations are already in place and the parties are working on future product cooperation.
- Continued Focus on Cost, Cash, and Regulatory ExecutionManagement plans to maintain cost and cash discipline without oversaving, continue addressing rising accreditation requirements, and focus on local activities increasingly requested by Asian and U.S. customers.
DE:SBS Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 31, 2027 | 2026 (Q4) | 0.85- | 0.59 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | 0.150.15 | 0.13 | 15.38% (+0.02) | |
| Aug 14, 2026 | 2026 (Q2) | 0.190.39 | 0.09 | 327.78% (+0.29) | |
| May 11, 2026 | 2026 (Q1) | ―- | 0.12 | ― | |
| Apr 28, 2026 | 2025 (Q4) | 0.00-0.12 | 0.12 | -195.83% (-0.23) | |
| Nov 07, 2025 | 2025 (Q3) | 0.170.13 | 0.05 | 160.00% (+0.08) | |
| Aug 19, 2025 | 2025 (Q2) | ―0.09 | 0.29 | -68.97% (-0.20) | |
| May 30, 2025 | 2025 (Q1) | ―- | 0.07 | ― | |
| May 19, 2025 | 2024 (Q4) | ―0.12 | 0.07 | 71.43% (+0.05) | |
| Oct 25, 2024 | 2024 (Q3) | 0.380.05 | 0.47 | -89.36% (-0.42) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
